Χώρα: Ηνωμένο Βασίλειο
Γλώσσα: Αγγλικά
Πηγή: VMD (Veterinary Medicines Directorate)
Sulfadiazine, Trimethoprim
Vetoquinol UK Ltd
QJ01EW10
Sulfadiazine, Trimethoprim
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Antimicrobial
Authorized
1994-05-11
Vm 08007/4055 February 2005 SPC_121510.DOC Page 1 of 4 Vm 08007/4055 PART II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Trimedoxine 80 Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Trimethoprim 80mg and Sulfadiazine 400mg. FOR A FULL LIST OF EXCIPIENTS, SEE SECTION 6.1 3. PHARMACEUTICAL FORM Tablet. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES When susceptible organisms are present, the product may be effective in treating the following conditions: alimentary tract infections, respiratory and urogenital infections, skin and wound infections and eye and ear infections. 4.3 CONTRA-INDICATIONS Trimedoxine 80 tablets are not suitable for use in cats. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No special warnings. 4.5 SPECIAL PRECAUTIONS FOR USE (I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS No special precautions. (II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS Wash hands after use. If accidental ingestion occurs, seek medical advice immediately. For animal treatment only Vm 08007/4055 February 2005 SPC_121510.DOC Page 2 of 4 Vm 08007/4055 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) A low incidence of polyarthropathy and keratoconjunctivitis sicca (dry eye) has been reported in dogs following oral administration of potentiated sulphonamides. If either of these conditions occur, it is recommended that medication is stopped and that future treatment with similar products is avoided. Sulphonamide hypersensitivity is rare in companion animals but should be considered in cases of unexpected responses to treatment. 4.7 USE DURING PREGNANCY, LACTATION OR LAY Can be safety administered during pregnancy and lactation. 4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION No known interactions. 4.9 Amounts to be administered and administration route The daily dose is one tablet per 16kg bodyweight administered orally, pro Διαβάστε το πλήρες έγγραφο